The Solutions Catalog

Part of The Core Competencies Guide for Health Systems

Review fit-for-purpose solutions to implement your digital strategy for improving equity in access to cancer treatment and reducing patient financial toxicity

Go to the Core Competencies Guide online



CO-HOSTED BY





Who Should Use This Solutions Catalog



Why Use The Solutions Catalog?

Digital health division leadership, oncology service line leadership, and individual cancer care providers can use this resource to:

- Choose fit-for-purpose solutions from the market to implement your digital strategy.
- → Identify the impact of on-the-market solutions on measures that matter to your health system and patients.



The Solutions Catalog as Part of a Digital Oncology Strategy

Solutions listed in this resource can be taken off the shelf to support your implementation of the <u>CancerX Core Competencies Guide</u> for Health Systems.



Example Solutions across the Cancer Care Continuum

HEALTH SYSTEM SOLUTIONS	Solutions (1),(2),(3), (4),(5)&(6): Digital platforms for diagnosis & treatment planning	Solutions (1),(2),(3)&(4): Remote patient monitoring & decentralized trial platforms to extend & diversify clinical trials	
Solutions: (1),(2),(3)&(4): Digital platforms to expedite diagnosis & treatment	Solutions (1),(2)&(3): Digital platforms for clinical trial matching & trial site activation	Solution (1).(2),(3),(4),(5): Digital platforms to improve access, reduce cost of treatment	Solution: Virtual care platform to improve access to care in survivorship
SCREENING + DIAGNOSIS	TREATMENT +	END OF LIFE CARE	SURVIVORSHIP
Solution: At-home screening and detection tests	Solutions: (1) &(2) Direct-to-patient platforms to improve patient cost & psychosocial outcomes	Solutions (1),(2),(3),(4) (5),(6)&(7): Patient navigation applications for clinical, financial, and psychosocial guidance	Solution: Digital solution for psychosocial support
PATIENT-FACING SOLUTIONS	Solution: Digital marketplace for clinical trials		CANCERX 3

Digital Genetics Platform to Expedite Diagnosis & Treatment



About CancerIQ

CancerIQ is a precision health platform that enables providers to automate germline and somatic genetic testing and use the information to prevent, detect, and treat cancer at scale. Integrated into EHR workflows, CancerIQ amplifies the reach of genetics teams by translating patient risk information into actionable care pathways along the entire continuum of cancer care. **THE PROBLEM** | Evolving guidelines are rapidly expanding genetic testing eligibility in oncology, but genetics workforce capacity remains a major barrier to widespread implementation of precision cancer prevention, early detection, and treatment.

THE SOLUTION | The CancerlQ platform provides a full suite of services, including on-demand patient education, telegenetic counseling, and virtual health navigation, so providers in any care setting are equipped to help patients get ahead of cancer.

- <u>Scale</u> precision cancer prevention, early detection, and treatment.
- <u>Double</u> genetic counseling service capacity and <u>quadruple</u> genetic testing uptake.
- <u>Significantly improve cancer screening</u>
 <u>compliance</u>, shift cancer diagnoses to earlier stages and generate downstream revenue.



Digital Imaging Platform to Guide Expedited Diagnosis & Treatment



About Lunit INSIGHT

Utilizes AI and deep learning technologies to aid in imaging diagnostics. This system integrates seamlessly with existing radiology workflows to transform providers' image reading experience.

See <u>example Key Performance Indicators</u> your system can use to define and measure successful implementation of this type of solution.

THE PROBLEM | Consequences of delayed diagnosis for lung and breast cancer include: increased health system and patient financial expenditures, as well as poorer health outcomes and lower survival rates.

THE SOLUTION | Lunit INSIGHT provides AI-enabled solutions for improving chest x-ray (CXR) and mammogram (MMG) screening diagnostics, that enables timely treatment.

THE IMPACT | *Lunit INSIGHT* improves patient access to care options and reduces overall costs. This is made possible by:

- <u>96-99% accuracy rates</u>.
- <u>20% increase in the detection rate</u> for early diagnoses.
- Reading time <u>reduced by 40%</u>.
- <u>30% decrease in recall rates</u>.



Point of Care Solution for Patient Data Sharing



About Navya

The Navya Cancer Data Model leverages AI and machine learning to synthesize patient data, automate workflow, and facilitate expert consensus via asynchronous tumor boards. This enables faster decision-making and reduced time to treatment. Navya's ExpertApp delivers a case summary and structured treatment options derived from patient records, published evidence, and expert guidelines. An automated patient letter is generated in easy-to-read terms outlining the oncologist's proposed treatment plan for the patient and family to review. **THE PROBLEM** | Costs to patients can increase when more time is spent accessing and managing patient data information and when access to expert input is difficult to obtain.

THE SOLUTION | Navya's ExpertApp is a point-of-care solution for oncologists, specialists, and all care team members, enabling them to share patient data within the clinical setting.

- The inclusion of Navya's plan increased compliance with NCCN and NCG guidelines by **15%**.
- Solutions like Navya eliminate the travel burden and significantly reduce cost and wait time for patients with limited access to academic medical centers. <u>Median travel was reduced</u> from **761 miles** to **0 miles**, costs reduced by \$1,145, and time from **3 days** to **1 day**.
- <u>97% of U.S. patients</u> receiving the Navya solution experienced significant anxiety relief due to 24 hours turnaround time.



Al-driven Cancer Diagnostic Platform

Beyond Diagnostics

nou

About Noul

Noul Co., Ltd. (Korea) presents its innovative Al-driven cancer diagnostic platform, miLab[™] CER. This innovation automates staining, imaging, and analyzing cervical cells, delivering Al-based results according to the six diagnostic categories of the Bethesda System (TBS). miLab[™] CER offers a comprehensive digital solution that replaces the traditional, labor-intensive process with a single automated device. Noul aims to cover the underserved 90% of the burdened population spread across the deepest side of the globe, reducing unnecessary deaths worldwide. **THE PROBLEM** | Identifying the vital abnormal cells among many normal non-cancer cells is crucial yet labor-intensive, time-consuming, and prone to errors—especially in regions with workforce shortages and high labor costs.

THE SOLUTION | Noul's compact AI-embedded solid staining solution, miLab[™] CER, has significantly enhanced the accessibility of the gold-standard Pap test for the U.S. and other globally burdened populations.

- **Ensure** reliable, high-quality AI analysis results <u>within 30</u> <u>minutes</u>, significantly reducing the current 2 to 60+ day retrieval time.
- **Enhance** quality assurance and management with automated analysis to <u>improve test consistency and</u> <u>reliability.</u>
- **Enable** equitable healthcare access, facilitating early screening for timely treatment, and filling workforce gaps in pathology minimizing health disparities



Clinical Decision Support for Diagnosis



About Deep Bio's DeepDx® Prostate

DeepDx® Prostate is an Al-powered software for the assessment of prostate cancer. The software uses deep learning to analyze digital whole slide images (WSIs) of hematoxylin and eosin-stained prostate core needle biopsies to provide automated prostate cancer detection, Gleason scoring, and tumor length and volume measurements. The Al-powered solution empowers pathologists to make more accurate diagnosis with confidence. **THE PROBLEM** | Diagnostic ambiguity in prostate cancer drives the need for a more consistent and reproducible method of grading. Further, pathologist workforce shortages produce prolonged diagnostic wait times and disparate health outcomes, particularly for patients in remote, rural, and economically disadvantaged areas.

THE SOLUTION | DeepDx® streamlines clinical workflows to ensure swift access to reliable diagnoses. By mitigating the financial impact of misdiagnoses, overdiagnosis, or false positives, DeepDx® Prostate also alleviates the financial burden on healthcare systems and patients associated with unnecessary investigations and treatments.

- **Diagnostic Efficiency**: <u>Decreases turnaround times</u> for timely and accurate diagnoses.
- Equitable Access to Health Care: <u>Bridges the</u> <u>pathologist workforce gap</u>, particularly in remote areas, reducing health disparities.
- **Financial Impact**: Reduces costs associated with traditional pathologist workflows, multiple consultations, and low-value care.



Clinical Decision Support for Treatment Planning



About Flatiron Assist

Flatiron Assist is a clinical decision support platform embedded into the EHR that prioritizes evidence-based medicine, clinical research, and site-specific preferences at the point of care. **THE PROBLEM** | Variation in care delivery can negatively impact patient access to guideline-concordant care and cancer outcomes.

THE SOLUTION | Flatiron Assist[™] is a customizable oncology-specific clinical decision support platform that allows clinicians to stay up to date with evolving treatment guidelines and relevant clinical trials while reducing variation in care delivery.

- **88%** NCCN guideline concordance in treatment planning.
- **84%** clinician adoption after 1 year.
- **10%** reduction in insurance denial rates.
- **2** day improvement in time to prior authorization.
- **119-day** faster adoption of treatment replacements for NCCN-deprecated regimens in prostate cancer.
- **44%** reduction in unique treatment regimens ordered across cancer centers.



Clinical Decision Support for Treatment Planning



About Genomate

Genomate has built the first general computational reasoning AI engine that helps oncologists determine the optimal targeted therapy for every cancer patient based on the individual molecular profile of their tumor. **THE PROBLEM** | Although precision oncology stands as the optimal approach for cancer care, current targeted therapies are only focused on some of the most frequent cancer genes and often fail to work due to the unique molecular background of each tumor.

THE SOLUTION | Genomate helps identify the right targeted therapies for the complex molecular landscape of each individual tumor. It enables optimal treatment decisions for each patient, thereby saving money on costly and ineffective therapies, and ultimately improving treatment outcomes.

- **70%** of patients have better access to more effective therapies when considering Genomate scores.
- **<u>72%</u>** of pediatric cancer cases have been paired with targeted treatment when using Genomate.
- 103% improvement of median progression-free survival (mPFS) when using (versus not using) Genomate for treatments.



Digital Platform for Diagnosis

SOPHIA GENETICS"

About SOPHiA DDM™

SOPHiA DDM[™] is a cloud-based platform that transforms unstructured and siloed multimodal data into comprehensive insights, originally designed to address the intricate challenges of NGS. Powered by Al/ML, the SOPHiA DDM[™] Platform automatically processes and accurately analyzes a vast amount of real-world health data in real-time, spanning multiple disease areas from oncology to inherited disorders. **THE PROBLEM** | Relying on external send-out services introduces challenges, including prolonged turnaround times and a lack of control over sample quality, which can compromise the dependability of genomic data and delay patient access to care. Equally critical is the need for a technology that seamlessly integrates with existing infrastructure and navigates staffing constraints to substantially reduce costs and meet the evolving needs of laboratories.

THE SOLUTION | SOPHiA DDM[™] is a universal platform that integrates into diverse laboratory environments and existing technologies, ensuring that laboratories, can harness the power of NGS applications without extensive modifications. The Platform empowers users to enhance their in-house capabilities by enabling them to perform testing on their samples, retain custody and data, and share insights to foster collective intelligence.

- **<u>Reduced Turnaround Time</u>**: Streamlines data-to-insights workflow significantly to reduce time needed to solve genomic cases by approximately 50-60%.
- <u>Accelerated Adoption</u>: Supports adoption of new NGS-based applications in approximately 9 months, compared to the typical 18-month timeframe.



Clinical Decision Support for Treatment Planning



About Volpara's Risk Pathways Tool

Risk Pathways is a complete program for identifying and managing higher-risk patients earlier on in the continuum of care. This clinical decision support tool applies world-class knowledge about risk and genetics to prevent late-stage breast cancer. The tool seamlessly integrates with health system electronic health record to allow personalized screening at the population level so that fewer people are diagnosed with late-stage cancers. **THE PROBLEM** | Many factors contribute to <u>low</u> <u>screening guideline adherence</u> for screenable cancers and <u>later-stage cancers are more costly to</u> <u>treat</u>.

THE SOLUTION | Volpara's Risk Pathways identifies lifetime and hereditary risk in patients across settings. The workflow and clinical-decision support tool integrates seamlessly with EHRs allowing the automatic initiation of the assessment process for people presenting for preventative medical care.

- Supports personalized screening strategies in high-risk patient populations and <u>expedites</u> <u>time to diagnosis</u>.
- Provides a risk score for each patient along with guidelines, recommendations, and tools to bifurcate patients and suggest a personalized approach to screening and management.



Digital Platform to Improve Access to Precision Oncology as Part of Treatment Planning



About CureMatch

CureMatch offers therapy decision support to physicians navigating the molecular complexity of cancer. The CureMatch Oncology Report ranks and scores custom combinations of approved drugs for a patient's molecular profile. The algorithms analyze a patient's clinically significant NGS markers from any lab report, sample, and cancer type against a curated knowledge base. Clinical trials with matched drug combinations are included. Drug resistance markers are also listed to help *do no harm*. CureMatch equips oncologists with the molecular insights of a tumor board and was granted the first CPT code by the AMA in the Assistive Intelligence category.

THE PROBLEM | The complexity of choosing optimal drugs or drug combinations to address a patient's entire cancer-driving molecular profile is a bottleneck in precision oncology. Lack of access to molecular tumor boards in rural communities hampers the adoption of personalized precision medicine.

THE SOLUTION | A CureMatch analysis generates drug combinations and monotherapy options matched on a molecular basis in a personalized report within three business days of submission of a patient's NGS report(s). CureMatch includes links to clinical trials that evaluate any of the prioritized drug combinations listed in the report.

- **Improved PFS and OS** of patients on molecularly matched therapies, as evidenced by <u>clinical trials</u>.
- **Better clinical decision support** for addressing cancer complexity, taking action on unique combinations of markers with combinations of matching drugs or monotherapy options.
- **Reduced risks of clinical and financial toxicity** or ineffective treatment choices due to molecular caveats of an individual's cancer.
- Patients and physicians in rural communities have prompt access to information currently only accessible via tumor board discussions.
- Increased awareness/exposure to clinical trials focused on combinations of drugs related to multiple molecular markers in a patient.



AI/ML Algorithm for Clinical Trial Matching



About Massive Bio's SYNERGY-AI

Patients input their medical data to the SYNERGY-AI platform. Data is analyzed to match patients with clinical trials or treatments and providers can access a dashboard that offers insights into patient needs, potential trial matches, and treatment outcome. **THE PROBLEM** | Many patients are unaware of or unable to participate in clinical trials due to stringent eligibility criteria, lack of information about trial availability, and logistical challenges.

THE SOLUTION | SYNERGY-AI is a deep, learning-based Natural Language Understanding Engine combining natural language processing, decision trees, multilayer perceptron models, and report generation. The platform uses human support to deliver recommendations that are enacted by a case management team.

- **63%** of patients were found eligible for at least one clinical trial; **58%** of those trials were within 50 miles of the patient's residence.
- **14%** of patients evaluated by SYNERGY-AI enrolled in the recommended clinical trial; much higher than the national average of **3%**.
- Recommended treatments resulted in an average savings of **\$39,194** per patient.



Digital Solution for Clinical Trial Site Activation

"I"EMPUS

About Tempus TIME

Tempus TIME uses automatic pre-screening methods to identify clinical trial opportunities based on patient medical history and diagnoses and facilitates rapid study start up including IRB approval and contract execution. **THE PROBLEM** | In some cases, a patient may meet eligibility criteria for a clinical trial not yet opened within their home health system.

THE SOLUTION | Tempus TIME is a rapid clinical trial site activation program that increases access by rapidly activating clinical trials that are in its network in locations that are close to patients.

THE IMPACT | Sites are activated within an average of **10** business days of patient identification following the execution of a clinical trial agreement, central IRB approval, and a site initiation visit. Patient consent and enrollment is completed by site team after activation.



Remote Patient Monitoring for Earlier Intervention

TEMP[®]TRAQ[®]

^{By} blue spark

About Blue Spark Technologies' TempTrag

TempTrag is an FDA Cleared Class II medical device that gives healthcare providers the first wireless continuous temperature monitor in the form of a soft, comfortable, disposable patch. TempTrag can significantly improve the way temperature is measured in the clinical environment and provide clinicians a quicker, easier, and more effective way to measure temperature.

THE PROBLEM | Temperature is taken intermittently, potentially missing the onset of fever and delaying intervention, which results in extended hospitalizations, increased cost of care, and reduced patient satisfaction.

THE SOLUTION | TempTrag is a continuous patient temperature monitoring device for early identification and intervention of fevers related to neutropenic fever and cytokine release syndrome.

- Early identification and intervention for fever-fevers caused by CAR-T CRS were detected an average of 4.4 hours earlier than the standard of care.
- Allows expedited access to care through real-time remote patient monitoring, increasing the communication exchange between cancer patients and their care team.
- Allows high-risk patients to be monitored at home, reducing the cost of care and financial toxicity.



Remote Patient Monitoring & Decentralized Clinical Trials



About Folia Health

Facilitates research through the collection of home-reported outcomes (HROs) that capture patients' day-to-day experiences and observations as part of remote patient data collection. Folia Health currently serves more than 20,000 patients that track over 10 cancer types and contribute HRO data.

THE PROBLEM | There are several challenges associated with patient accrual and participation in clinical trial including geographical barriers, mobility limitations, longitudinal data collection, high travel costs, and low patient engagement.

THE SOLUTION | Folia Health is a digital health platform that improves access to cancer care and research opportunities by providing at-home, remote participation for patients.

- Gives access to over **20,000** patient users who participate in in-home research.
- Continuous remote monitoring facilitates longitudinal data collection and improved trial accrual.
- Reduces patient travel costs associated with in-person clinical trials.



Digital Platform for Decentralized Clinical Trials



About Medable

Medable accelerates clinical development with its award-winning digital platform for sites, sponsors, and patients. Medable's oncology offering is designed to streamline and enhance clinical trial processes for oncology research and has been deployed in more than 300 trials in 60 countries, serving more than one million patients globally. **THE PROBLEM** | Exposure risks and travel inconveniences are barriers to accessible clinical trials, particularly for immunocompromised oncology patients. Enrollment, retention, and efficient trial conduct barriers also complicate trials and delay patient access to precision cancer treatment.

THE SOLUTION | Medable provides a comprehensive suite of technologies that enable remote patient monitoring, seamless data collection, and real-time collaboration among researchers, clinicians, and patients. The platform aims to accelerate the development of new cancer treatments while improving patient outcomes, reducing costs, and ensuring compliance with regulatory requirements.

THE IMPACT

- Enhanced Patient Safety: Improved capacity of clinical staff to detect adverse events earlier than ever¹
- Improved Trial Efficiency & Experience: 25% reduction in study build time¹
- Return on Investment: Shorter development times, lower clinical trial screen failure rates, and fewer clinical trial protocol amendments <u>leading to cost savings</u>.

¹Source: Medable performance data through 2024. Available upon request.



Virtual Site for Decentralized Clinical Trials



About Science 37 Metasite

Science 37 Metasite is powered by a proprietary platform that guides the workflow of patients and study staff (investigator, nurse, and coordinator), and captures study data without the need for manual reentry. This centralization of people, processes, and platform delivers built-in protocol compliance.

See <u>example Key Performance Indicators</u> your system can use to define and measure successful implementation of this type of solution.

THE PROBLEM | The average trial start-up time is 31.4 weeks and 80% of trials are delayed due to issues with enrollment. Further, average trial retention rates are 70%.

THE SOLUTION | The Science 37 Metasite is a virtual trial site that allows patients and providers access to trials no matter their geographic location.

- Trial start-up times are **2x** faster compared to traditional site-based studies.
- Centralized patient engagement ensures 100% patient follow up and access to patient population that is **3x** more diverse than the industry average.
- 96% of patients retained on trials.



Virtual Care Platform to Improve Access & Reduce Cost of Treatment



About Bulldog Medical

Bulldog Medical completes rapid virtual work-ups via state-licensed oncologists & nurse practitioners to move a potential onset patient quickly through Labs, Imaging, and Biopsy. If cancer is diagnosed, Bulldog provides a detailed referral plan and essential patient and family education.

See <u>example Key Performance Indicators</u> your system can use to define and measure successful implementation of this type of solution.

THE PROBLEM | The average time to diagnosis for cancer patients with solid tumors is **5.2 months**. This delay often reduces the number of treatment options and increases the cost of treatment for systems and patients.

THE SOLUTION | Bulldog Medical provides virtual work-ups, as well as an emphasis on germline and somatic profiling to speed time to diagnosis.

- Reduces time to diagnosis and time to treatment initiation by as much as **90%**.
- Enures full access to the clinical benefits of germline and somatic profiling, increasing trial and precision treatment options.



Digital Platform to Improve Access & Reduce Cost of Treatment



About The Leukemia & Lymphoma Society's Referrals Application

The Leukemia & Lymphoma Society's platform is an EHR application that leverages FHIR (Fast Healthcare Interoperability Resources) technology to help providers seamlessly connect patients to LLS Information Specialists and, in turn, all support pathways offered by LLS, including financial support services. **THE PROBLEM** | The high cost of cancer care is a significant barrier between many patients and the treatment, care, and resources they need. LLS offers a variety of patient services, including financial assistance programs (e.g., co-pay, travel, urgent non-medical expenses) but pathways for referral are underused.

THE SOLUTION | The application is implemented via Best Practice Advisory (BPA) technology within the EHR. The BPA appears for a provider of a patient with a blood cancer, prompting them to discuss the benefits of connecting with LLS. When the patient agrees, the provider completes a form in the EHR, which includes the ability to comment on specific patient needs. Providers also receive updates on patients who are connected to LLS.

- Reduces patient navigation workload and enables easier connection to resources.
- Increases access to timely support
 over 90% of patients referred were not previously connected with LLS resources and 46% were referred within 90 days of diagnosis.



Digital Platform to Improve Access & Reduce Cost of Treatment



About MedHaul

MedHaul enables tailored transportation solutions for chronically ill patients, ensuring safety, reliability, and inclusivity. Through a unified, real-time platform, healthcare providers, patients, caregivers, administrators, and transportation operators are connected, facilitating personalized rides such as assisted, wheelchair, and stretcher transportation, along with various ancillary accommodations like car seats, isolation trips, bariatric needs, short trips for lab and injection visits and more. **THE PROBLEM** | Inequities in access to cancer care and clinical trials, coupled with high levels of patient financial toxicity, present significant barriers to effective treatment and research participation. Transportation challenges, socioeconomic disparities, and inadequate infrastructure delay access to care, particularly for vulnerable populations. Furthermore, substantial transportation expenses worsen financial toxicity, increasing stress and compromising adherence

THE SOLUTION | Through MedHaul's digital platform, users can schedule on-demand or future rides and track rides in real-time, receive notifications via SMS and conversational AI, and provide feedback for an enhanced experience. Providers and stakeholders can coordinate and monitor transportation arrangements, integrating them into routine cancer care

THE IMPACT

- Achieved a 25% reduction in missed appointments¹
- Improved patient appointment timeliness by 52%¹
- 20% of zip codes served represent the top poverty zip codes in its corresponding state¹

¹Source: MedHaul utilization data through 2024



Virtual Care Platform to Improve Access & Reduce Cost of Treatment

Reimagine Care

About Reimagine Care

Reimagine Care supports patients with cancer by delivering a suite of clinical solutions designed for extending care beyond the clinic, including 24/7 symptom management, treatments, medication management, and whole person support. Reimagine Care provides the clinical expertise and enabling technologies to help health systems and oncology practices transition from facility-based care to a hybrid model. THE PROBLEM | The cancer care journey is fragmented and inconsistent across settings of care, leading to challenges in patient management, increasing costs, lowering satisfaction, and contributing to poorer outcomes. These issues are magnified by an overburdened and shrinking oncology workforce that wants to deliver more holistic care for patients outside the walls of clinics but doesn't have the resources or tools to do so independently.

THE SOLUTION | Reimagine Care is a patient-focused virtual cancer care platform that integrates an AI-enabled virtual assistant, the latest evidence-based care pathways, proactive check-ins, education and ePRO with 24/7 access to clinical oncology experts and the ability to deploy supportive care into patient homes.

- Improved Patient Access and Reduced HCU: 97% of all patient interactions virtually with less than 2% of interactions requiring referral to the ED.
- <u>Improved Patient Engagement</u>: **81%** patient engagement at 60 days.



Digital Platform to Improve Access & Reduce Cost of Treatment

TAILORMED

About TailorMed

TailorMed offers the nation's largest network of providers, pharmacies, and life science companies dedicated to tackling healthcare affordability. Its comprehensive technology suite empowers network constituents to proactively identify financially at-risk patients and maximize available assistance, drawing on 6,000-plus resources. TailorMed's solutions have now been implemented across more than 700 hospitals, 1,200-plus clinics, and over 600 pharmacies. **THE PROBLEM** | A cancer diagnosis takes a toll on patients, medically and financially. While numerous assistance programs exist to help patients offset costs of care, these resources remain underutilized and reliant on manual processes. This leads to worsened patient outcomes and experiences, as well as uncompensated care and bad debt.

THE SOLUTION | Using predictive analytics, TailorMed enables health systems and other organizations to flag patients in need. Based on the patient's diagnosis, insurance, and other factors, it creates a comprehensive list of funding opportunities – including manufacturer copay assistance, foundation grants, and more – and streamlines enrollment.

- Patient Access and Affordability: Has helped secure more than \$4 billion in patient financial resources.
- Financial Performance: Supports increase in revenues and reduces uncompensated care and bad debt.
- Workforce Efficiency: Reduces manual navigation processes, empowering staff to connect more patients with assistance and quickly follow up on claims. In one case, enabled a 49% reduction in A/R days on copay assistance claims in six months.



Virtual Care Platform to Improve Access to Care in Survivorship

Biofourmis

About BioforumisCare

Biofourmis Care is a hospital at home platform that supports continuous patient monitoring, virtual visits, care coordination, and transitional care. **THE PROBLEM** | Care transitions are often associated with adverse events, increased cost, and reduced patient satisfaction

THE SOLUTION | The Biofourmis Care platform enables virtual consults and triage, remote patient monitoring through clinically validated devices, and scalable care management capabilities that are similar to in-patient workflows (via EMR integration).

- **70%** <u>reduction in readmissions</u> for patients receiving acute care at home.
- **38%** <u>average cost reduction</u> for acute care patients receiving care at home.
- Increased <u>bed-days saved</u> and <u>patient</u> <u>satisfaction</u>.
- <u>Maximize patient-to-staff ratio</u> with a scalable, technology-enabled platform.



At-Home Screening & Detection Tests

Galleri®

About Galleri

The Galleri test applies machine learning and pattern-recognition to identify abnormal DNA methylation patterns and detect a cancer signal from a single blood draw. **THE PROBLEM** | Early-stage cancer is an average of <u>3x less expensive</u> to treat vs late-stage in the first year after diagnosis.

THE SOLUTION | Galleri is a multi-cancer early detection test, that allows patients to screen at home for a signal shared by more than 50 types of cancer.

- Gives providers a chance to screen for cancers that often remain asymptomatic until it is too late to meaningfully intervene.
- In <u>one clinical study</u>, Galleri approximately doubled the number of cancers detected with recommended screening.
- <u>88% accuracy</u> in predicting the first or second Cancer Signal Origin.



Direct-to-Patient Solution to Improve Patient Cost & Psychosocial Outcomes



About Cancer Support Community's My Care Report

My Care Report Platform screens for psychosocial distress and health-related social needs, provides automated tailored referrals and digital resources, and supports individual case management by tracking referral history and status. The digital platform houses CancerSupportSource (CSS), a reliable, validated, multidimensional distress screening tool, and CMS's screener for health-related social needs and financial toxicity.

See <u>example Key Performance Indicators</u> your system can use to define and measure successful implementation of this type of solution. **THE PROBLEM** | Unsupported distress can have a negative financial impact on patients and on institutions.

THE SOLUTION | My Care Report Platform supports providers to quickly and efficiently identify patients who have clinically indicated levels of distress and/or specific unmet health-related social needs and connect them with support and financial services, tailored resources, educational materials.

- Remote patient screening can be completed in minutes to generate patient and provider-facing resource reports.
- Screening results in a significant decrease in emergency department use (<u>50% reduction in</u> <u>one study</u>) and a shift from higher cost services to lower cost nonemergent and preventive care, supporting comprehensive, high quality, and patient-centric cancer care.



Digital Marketplace for Clinical Trials

PPower

About Power

Patients can search and sign up for trials that meet their specific criteria, complete a pre-screen survey tailored for each trial, and choose a site for trial participation based on plain text information provided about things like: eligibility criteria, timeline, safety and efficacy data, and research team expertise among others. **THE PROBLEM** | Approximately <u>85%</u> of patients are either unaware of clinical trials or lack information about trial opportunities as a care option at the time of a cancer diagnosis.

THE SOLUTION | Power is a patient-centric clinical trial marketplace that allows patients and providers to find and sign up for clinical trials, and allows trial sites to connect with patients directly.

- Trials available for more than **40** oncology indications.
- Connects sites with a broad, diverse and engaged source of patients, with over 58% of oncology participants on Power being non-white.
- Referred patients to over **9,000** clinical trials.



Patient Navigation Application: Financial Guidance



About Cedar

Cedar is committed to improving the healthcare financial experience for all. Cedar brings consumer-grade engagement technology to the end-to-end patient journey, making it easy and affordable for patients to prepare for their visits and pay their bills. **THE PROBLEM** | More than 100 million Americans struggle with medical debt, yet many of these individuals are unable to access financial assistance. This is largely due to a lack of awareness about available options or potential eligibility, coupled with difficulties navigating the application process.

THE SOLUTION | <u>Cedar's Affordability Navigator</u> is an integrated set of capabilities that connects each patient with the personalized financial assistance they may need to resolve their healthcare bills. In just a few taps, patients can easily access self-serve Medicaid enrollment, HSA funds, payment plans, and other resources during their most vulnerable moments.

- <u>47% increase</u> in payment plan creation for eligible patients.
- **<u>33% increase</u>** in patient use of HSA and FSA funds.
- <u>89% patient satisfaction</u> with the billing experience.



Patient Navigation Application: Clinical & Financial Guidance



The OncoPower application delivers:

- Access to second opinions, clinical guidance, and specialized providers.
- Access to partner-provided financial navigation resources and psychosocial support tools.

See <u>example Key Performance Indicators</u> your system can use to define and measure successful implementation of this type of solution.

THE PROBLEM | Disparities in access to cancer treatment and supportive care drive differential cost and health outcomes for cancer patients.

THE SOLUTION | OncoPower is an app- and web-based platform that provides cancer patients access to specialized providers, financial navigation resources, and psychosocial support.

- Reduces financial toxicity by connecting patients with partner-provided financial navigation services and in-app tools to manage the psychosocial impacts of cancer-improving treatment adherence and reducing administrative burden.
- Improves access to care by connecting users directly to a cancer type-specific panels of expert providers for clinical recommendations.



Patient Navigation Application: Psychosocial Guidance



About Osara Health

Osara Health is an oncologist-founded company that improves care outcomes for individuals impacted by cancer. The platform is provided as tech-enabled health coaching via a behavior change program. The Osara Health platform is grounded in evidence suggesting that patients actively involved in their healthcare achieve superior outcomes. Osara Health is improving the care experience, aiming to maximize health outcomes for both patients and their caregivers.

See <u>example Key Performance Indicators</u> your system can use to define and measure successful implementation of this type of solution. **THE PROBLEM** | For cancer patients and their caregivers, a lack of engagement, education, and support leads to expensive hospitalizations, as well as poor mental health and quality of life outcomes.

THE SOLUTION | Accessible via a digital platform, Osara Health offers 6-12 week programs where participants gain access to a dedicated health coach, digital resources, and an app for self- management strategies, such as symptom tracking and journaling. This virtual care complements traditional treatment, improving communication with care teams and contributing to better health outcomes.

- 32% of Osara Health participants report an improvement in mental health, and participants are 13x more likely to track their symptoms compared to the general population of cancer patients. This <u>can</u> <u>result in a reduction in ED visits and hospital</u> <u>readmissions</u>.
- Participants are 73% more likely to return to work, doing so 16.5 weeks sooner than non-participants.



Patient Navigation Application: Clinical & Financial Guidance

Outcomes4Me

About Outcomes4Me

Outcomes4Me uses AI and machine learning to help cancer patients navigate their care and access personalized treatment information. When patients provide their health information, the free platform offers both doctor-approved and FDA-approved guidance based on their diagnosis, as well as relevant clinical trials and genetic testing the patient might consider. **THE PROBLEM** | When a patient is diagnosed with cancer, the burden is often on them to self-educate and advocate. This proves challenging in a cancer treatment environment that is rapidly changing and is compounded by the fact that providers are overburdened in routine care provision and struggle to keep pace with evolutions in the evidence base.

THE SOLUTION | Outcomes4Me is a free direct to-patient digital application that integrates with the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) to provide patient-facing clinical guidance. The app also offers free access to oncology nurse practitioners and supports clinical trial recruitment through patient awareness and referrals.

THE IMPACT

- 9% of surveyed app users matched with a clinical trial via Outcomes4Me programming (compared to the national average of 5%)¹
- 36% of surveyed app users pursued genetic testing and 17% switched to a new treatment option under the guidance of their doctor after platform use¹

¹Source: Outcomes4Me patient member survey, 2023.



Patient Navigation Application: Clinical & Financial Guidance



About Spesana's Healthcare Platform

Spesana's Healthcare Platform is a digital overlay of any existing system including EMR and practice management, that aggregates information and enhances clinical, operational, and financial workflows with a patient-centric approach. **THE PROBLEM** | The barriers to patient navigation can be a combination of clinical, operational, and financial challenges resulting in disparities in access to cancer treatment.

THE SOLUTION | The Spesana Healthcare Platform is a digital interoperability overlay providing physicians with a holistic view of their patients along with clinical decision support tools updated with the latest clinical guidance. Integrated workflows allow for in-person or digital patient navigation to treatments and trials. A prior authorization solution is available to support treatment as well as integrated access to financial support programs to reduce financial toxicity for patients.

- Reduces physician and staff burnout <u>by optimizing</u> <u>the EHR</u> to address lack of critical information and manual, disconnected tasks associated with patient navigation.
- Supports <u>patient adherence to treatment and trial</u> <u>options</u> through prior authorization and financial assistance programs.



Patient Navigation Application: Clinical & Psychosocial Guidance



About Sidekick Health's Oncology Program

The program offers cancer-specific education and supports users with their sleep, mental resilience, nutrition, and physical activity. Through the care portal, the user's care manager, who leads their care plan, can remotely monitor the user's activity and symptoms.

See <u>example Key Performance Indicators</u> your system can use to define and measure successful implementation of this type of solution.

THE PROBLEM | The traditional approach to cancer care can limit access for rural communities and prevent communication with the care team outside of routine clinic appointments.

THE SOLUTION | Sidekick Health supports patients in the self-management of their cancer symptoms and side effects via a 13-week app-based program connected to a <u>digital care management platform</u>.

- Wide geographical reach, including urban and rural users across 46 US states.
- Positive impacts on emergency care use (<u>39%</u> reduction in ED utilization), admissions, outpatient care and prescription claims.
- **34%** of messages sent outside of office hours; median response time 1.5 hours
- 92% agreed it helped them handle their symptoms, and 94% agreed that it supported their journey.



Patient Navigation Application: Patient Access & Reduced Health Care Cost

Thype

About Thyme Care's Thyme Box

The Care Team uses Thyme Care's purpose-built tech -Thyme Box - to quickly synthesize information from electronic health records, claims, ADT events from health exchanges, and patient-reported outcomes, among others. Thyme Box then guides care teams with evidence-based navigation playbooks, and a readily available resource library, to address barriers to care.

See <u>example Key Performance Indicators</u> your system can use to define and measure successful implementation of this type of solution.

THE PROBLEM | Patient receipt of and adherence to cancer care can be impacted by poor patient literacy, poor trust of health care system, overall cost of treatment, and other challenges.

THE SOLUTION | Thyme Care supports patients throughout their cancer journey by connecting them to virtual care teams that help to expedite appointments, coordinate care, overcome challenges, and proactively manage symptoms.

- Improves care coordination by overcoming data silo barriers and providing individualized assistance to patients
- Helps secure oncology appointments within
 2 business days (industry average is 6 weeks)
- Achieved <u>\$594 PMPM savings</u> for managed population; a majority of savings from averted acute care utilization



Digital Solution for Psychosocial Support

Jasper

About Jasper Health

Jasper Health provides personalized digital and human-led supportive care services to cancer patients and their caregivers. Jasper provides psychosocial support through a blended-care patient experience model that enables members to meet with care coaches virtually and to receive self-paced activities and education materials.

See <u>example Key Performance Indicators</u> your system can use to define and measure successful implementation of this type of solution.

THE PROBLEM | The physical, emotional, social and practical aspects of a patient's cancer experience have significant impact–undermining quality of life, leading to avoidable ER visits, and making treatment adherence more challenging.

THE SOLUTION | Jasper's clinician-facing platform Care+ is supported by Al-driven workflow automation, omni-channel messaging and resource matching, which allows the development of personalized care plans to meet emotional wellness, sleep, nutrition and financial needs of members via its Care Companion application.

- **13.2%** reduction in ER visits; 91% of members reported they would consult Jasper and their care coach before going to the ER.
- **11.6%** reduction in hospitalizations for cancer patients when Jasper Health is incorporated into high-quality medical care.



More Resources for Your Digital Oncology Strategy

The Solutions Catalog as Part of a Digital Oncology Strategy

Solutions listed in this resource can be taken off the shelf to support your implementation of the <u>CancerX Core</u> <u>Competencies Guide for Health</u> <u>Systems</u>.

About CancerX

CancerX is a public-private partnership announced by The White House as a national accelerator to boost innovation in the fight against cancer as part of the reignited Cancer Moonshot. You can access more information and resources at <u>CancerX.Health</u>.

